{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:00:54Z","timestamp":1772114454408,"version":"3.50.1"},"reference-count":76,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2024.2798","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T12:27:30Z","timestamp":1730377650000},"source":"Crossref","is-referenced-by-count":8,"title":["Factors associated with immune\u2011related severe adverse events (Review)"],"prefix":"10.3892","volume":"22","author":[{"given":"Zhenzhen","family":"Su","sequence":"first","affiliation":[{"name":"School of Nursing, Peking University, Beijing 100191, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaomiao","family":"Guan","sequence":"additional","affiliation":[{"name":"School of Nursing, Peking University, Beijing 100191, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemin","family":"Lian","sequence":"additional","affiliation":[{"name":"School of Nursing, Peking University, Beijing 100191, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"issue":"e2","key":"key20241206115208_b1-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.4110\/in.2022.22.e2","article-title":"Immune checkpoint inhibitors in 10 years: Contribution of basic research and clinical application in cancer immunotherapy","volume":"22","author":"Lee","year":"2022","journal-title":"Immune Netw"},{"key":"key20241206115208_b2-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"key20241206115208_b3-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","article-title":"PD-1\/PD-L1 blockade therapy in advanced non-small-cell lung cancer: Current status and future directions","volume":"24 (Suppl 1)","author":"Xia","year":"2019","journal-title":"Oncologist"},{"key":"key20241206115208_b4-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"key20241206115208_b5-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: CardioOncology primer","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC CardioOncol"},{"key":"key20241206115208_b6-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"key20241206115208_b7-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"issue":"108353","key":"key20241206115208_b8-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108353","article-title":"Adverse events of immunotherapy in non-small cell lung cancer: A systematic review and network meta-analysis","volume":"102","author":"Zhou","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"key20241206115208_b9-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"key20241206115208_b10-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/j.cllc.2021.09.010","article-title":"Design and rationale for a phase III, double-blind, placebo-controlled study of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small-cell lung cancer: The AEGEAN trial","volume":"23","author":"Heymach","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"key20241206115208_b11-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: Protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"key":"key20241206115208_b12-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nrclinonc.2016.30","article-title":"Immunotherapy and stereotactic ablative radiotherapy (ISABR): A curative approach?","volume":"13","author":"Bernstein","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"key20241206115208_b13-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41571-021-00520-1","article-title":"Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC","volume":"18","author":"Grant","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"key20241206115208_b14-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: A meta-analysis","volume":"23","author":"Rubio-Infante","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"key20241206115208_b15-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejca.2020.01.013","article-title":"Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies","volume":"129","author":"Baldini","year":"2020","journal-title":"Eur J Cancer"},{"key":"key20241206115208_b16-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/2326-6066.CIR-19-0986","article-title":"Demographic factors associated with toxicity in patients treated with anti-programmed cell death-1 therapy","volume":"8","author":"Shah","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"key20241206115208_b17-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"9027","DOI":"10.1002\/cam4.3532","article-title":"Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy","volume":"9","author":"Kanjanapan","year":"2020","journal-title":"Cancer Med"},{"key":"key20241206115208_b18-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jgo.2021.10.002","article-title":"Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab","volume":"13","author":"Ksienski","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"key20241206115208_b19-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00262-020-02663-z","article-title":"Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: A systematic review and meta-analysis","volume":"70","author":"Guzman-Prado","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"key20241206115208_b20-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-022-00796-0","article-title":"The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy","volume":"29","author":"Assump\u00e7\u00e3o","year":"2022","journal-title":"J Biomed Sci"},{"key":"key20241206115208_b21-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2019.12.031","article-title":"Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)\/programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events","volume":"128","author":"Cortellini","year":"2020","journal-title":"Eur J Cancer"},{"issue":"489","key":"key20241206115208_b22-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03134-4","article-title":"Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab","volume":"19","author":"De Filippi","year":"2021","journal-title":"J Transl Med"},{"key":"key20241206115208_b23-MCO-22-1-02798","doi-asserted-by":"crossref","first-page":"S639","DOI":"10.1016\/j.jtho.2021.01.1168","article-title":"P78.05 Patterns of irAE during first line pembrolizumab for NSCLC: Incidence, risk factors, and impact on clinical outcome","volume":"16 (Suppl 1)","author":"Wood","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key20241206115208_b24-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/toxsci\/kfad033","article-title":"Pulmonary immune response regulation, genotoxicity, and metabolic reprogramming by menthol- and tobacco-flavored e-cigarette exposures in mice","volume":"193","author":"Muthumalage","year":"2023","journal-title":"Toxicol Sci"},{"issue":"1927313","key":"key20241206115208_b25-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1927313","article-title":"Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: A 10-year single-institution analysis","volume":"10","author":"Abdelrahim","year":"2021","journal-title":"Oncoimmunology"},{"key":"key20241206115208_b26-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the global burden of disease study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"issue":"1710389","key":"key20241206115208_b27-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1710389","article-title":"Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1\/PD-L1 checkpoint inhibitors: The multicenter FAMI-L1 study","volume":"9","author":"Cortellini","year":"2020","journal-title":"Oncoimmunology"},{"key":"key20241206115208_b28-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/CJI.0000000000000338","article-title":"Incidence and prediction of immune checkpoint inhibitor-related nephrotoxicity","volume":"44","author":"Sorah","year":"2021","journal-title":"J Immunother"},{"key":"key20241206115208_b29-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1210\/jc.2018-01430","article-title":"PD-1 inhibitor immune-related adverse events in patients with preexisting endocrine autoimmunity","volume":"103","author":"Akturk","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"key20241206115208_b30-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol"},{"key":"key20241206115208_b31-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/jnci\/djac046","article-title":"Pre-existing autoimmune disease and mortality in patients treated with anti-PD-1 and Anti-PD-L1 therapy","volume":"114","author":"Tang","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"key20241206115208_b32-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/j.amjcard.2020.02.016","article-title":"Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors","volume":"125","author":"Oren","year":"2020","journal-title":"Am J Cardiol"},{"issue":"3480","key":"key20241206115208_b33-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113480","article-title":"Pre-existing cardiovascular conditions as clinical predictors of myocarditis reporting with immune checkpoint inhibitors: A vigibase study","volume":"12","author":"Noseda","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20241206115208_b34-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3348\/kjr.2020.0728","article-title":"Immune checkpoint inhibitor with or without radiotherapy in melanoma patients with brain metastases: A systematic review and meta-analysis","volume":"22","author":"Kim","year":"2021","journal-title":"Korean J Radiol"},{"key":"key20241206115208_b35-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/CJI.0000000000000339","article-title":"Incidence and risk of colitis with programmed death 1 versus programmed death ligand 1 inhibitors for the treatment of cancer","volume":"43","author":"Miyashita","year":"2020","journal-title":"J Immunother"},{"key":"key20241206115208_b36-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"issue":"571135","key":"key20241206115208_b37-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.571135","article-title":"Comparative risks of high-grade adverse events among FDA-approved systemic therapies in advanced melanoma: Systematic review and network meta-analysis","volume":"10","author":"Huang","year":"2020","journal-title":"Front Oncol"},{"issue":"821626","key":"key20241206115208_b38-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.821626","article-title":"Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials","volume":"12","author":"Zheng","year":"2022","journal-title":"Front Oncol"},{"key":"key20241206115208_b39-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20241206115208_b40-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.euo.2021.03.001","article-title":"First-line Immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis","volume":"4","author":"Quhal","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"key20241206115208_b41-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann Oncol"},{"key":"key20241206115208_b42-MCO-22-1-02798","first-page":"177","article-title":"Progress on immunotherapy combined with chemotherapy, radiotherapy and targeted therapy for brain metastasis of small cell lung cancer","volume":"30","author":"Que","year":"2024","journal-title":"J Chin Oncol"},{"key":"key20241206115208_b43-MCO-22-1-02798","first-page":"292","article-title":"Meta-analysis of efficacy and adverse effects of different combination schemes of PD-1\/PD-L1 inhibitors in the treatment of ovarian cancer","volume":"25","author":"Zhang","year":"2024","journal-title":"Chin J Clin Obstet Gynecol"},{"key":"key20241206115208_b44-MCO-22-1-02798","first-page":"626","article-title":"Research progress of phototherapy combined with immune checkpoint inhibitors in the treatment of tumors","volume":"31","author":"Cheng","year":"2024","journal-title":"Chin J Cancer Biother"},{"key":"key20241206115208_b45-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1158\/2326-6066.CIR-18-0193","article-title":"A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing","volume":"6","author":"Lizotte","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"92","key":"key20241206115208_b46-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01544-0","article-title":"Oligometastasis and local ablation in the era of systemic targeted and immunotherapy","volume":"15","author":"Mazzola","year":"2020","journal-title":"Radiat Oncol"},{"key":"key20241206115208_b47-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.tcb.2018.08.005","article-title":"WNT signaling in cancer immunosurveillance","volume":"29","author":"Galluzzi","year":"2019","journal-title":"Trends Cell Biol"},{"key":"key20241206115208_b48-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jtho.2017.12.002","article-title":"PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes","volume":"13","author":"Du","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"4928","key":"key20241206115208_b49-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194928","article-title":"Severe late-onset grade III-IV adverse events under immunotherapy: A retrospective study of 79 cases","volume":"13","author":"L'Orphelin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20241206115208_b50-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ejca.2021.08.048","article-title":"The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry","volume":"158","author":"Ruste","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"key20241206115208_b51-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-022-00130-5","article-title":"Cardiotoxicity risk factors with immune checkpoint inhibitors","volume":"8","author":"Brumberger","year":"2022","journal-title":"Cardiooncology"},{"key":"key20241206115208_b52-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/07357907.2020.1721521","article-title":"Fatal adverse events associated with pembrolizumab in cancer patients: A meta-analysis","volume":"38","author":"Sher","year":"2020","journal-title":"Cancer Invest"},{"key":"key20241206115208_b53-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"1164309","key":"key20241206115208_b54-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1164309","article-title":"The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB","volume":"14","author":"Lou","year":"2023","journal-title":"Front Pharmacol"},{"key":"key20241206115208_b55-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2147\/CMAR.S293200","article-title":"Peripheral blood markers associated with immune-related adverse effects in patients who had advanced non-small cell lung cancer treated with PD-1 inhibitors","volume":"13","author":"Liu","year":"2021","journal-title":"Cancer Manag Res"},{"key":"key20241206115208_b56-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/CJI.0000000000000415","article-title":"Association of blood biochemical indexes and antibiotic exposure with severe immune-related adverse events in patients with advanced cancers receiving PD-1 inhibitors","volume":"45","author":"Zhao","year":"2022","journal-title":"J Immunother"},{"key":"key20241206115208_b57-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"695","DOI":"10.31557\/APJCP.2022.23.2.695","article-title":"Identifying early predictive markers for immune-related adverse events in nivolumab-treated patients with renal cell carcinoma and gastric cancer","volume":"23","author":"Takada","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1234142","key":"key20241206115208_b58-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1234142","article-title":"Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"e018306","key":"key20241206115208_b59-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018306","article-title":"Decreased absolute lymphocyte count and increased neutrophil\/lymphocyte ratio with immune checkpoint inhibitor-associated myocarditis","volume":"9","author":"Drobni","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"862752","key":"key20241206115208_b60-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.862752","article-title":"Elucidation of the application of blood test biomarkers to predict immune-related adverse events in atezolizumab-treated NSCLC patients using machine learning methods","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"key20241206115208_b61-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"key":"key20241206115208_b62-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41591-019-0523-2","article-title":"A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis","volume":"25","author":"Johnson","year":"2019","journal-title":"Nat Med"},{"key":"key20241206115208_b63-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00262-020-02793-4","article-title":"Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents","volume":"70","author":"Zamora","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"key20241206115208_b64-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"key20241206115208_b65-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"295","DOI":"10.21037\/tlcr-22-72","article-title":"Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer","volume":"11","author":"Chao","year":"2022","journal-title":"Transl Lung Cancer Res"},{"issue":"97","key":"key20241206115208_b66-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010097","article-title":"Plasma biomarkers screening by multiplex ELISA assay in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"13","author":"Costantini","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20241206115208_b67-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cytogfr.2024.08.003","article-title":"Cytokines on the way to secretion","volume":"79","author":"Kaminska","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"issue":"e2004433","key":"key20241206115208_b68-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202004433","article-title":"Cytokines: From clinical significance to quantification","volume":"8","author":"Liu","year":"2021","journal-title":"Adv Sci (Weinh)"},{"issue":"e132334","key":"key20241206115208_b69-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132334","article-title":"MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors","volume":"5","author":"Marschner","year":"2020","journal-title":"JCI Insight"},{"issue":"90","key":"key20241206115208_b70-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0408-9","article-title":"A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab","volume":"6","author":"Friedlander","year":"2018","journal-title":"J Immunother Cancer"},{"key":"key20241206115208_b71-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10637-020-00954-x","article-title":"Correction to: Germinal Immunogenetics predict treatment outcome for PD-1\/PD-L1 checkpoint inhibitors","volume":"39","author":"Refae","year":"2021","journal-title":"Invest New Drugs"},{"issue":"756872","key":"key20241206115208_b72-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.756872","article-title":"Intestinal microbiome associated with immune-related adverse events for patients treated with anti-PD-1 inhibitors, a real-world study","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"key20241206115208_b73-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nri.2017.7","article-title":"Dysbiosis and the immune system","volume":"17","author":"Levy","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"key20241206115208_b74-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"key":"key20241206115208_b75-MCO-22-1-02798","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1158\/1078-0432.CCR-18-4083","article-title":"Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors","volume":"25","author":"Ji","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"e002732","key":"key20241206115208_b76-MCO-22-1-02798","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002732","article-title":"Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis","volume":"9","author":"Bjursten","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T09:52:18Z","timestamp":1733478738000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2024.2798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10,31]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2024.2798","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]},"article-number":"3"}}